Cargando…
Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes
BACKGROUND: Recent advances in nanomedicine have shown the great interest of active targeting associated to nanoparticles. Single chain variable fragments (scFv) of disease-specific antibodies are very promising targeting entities because they are small, not immunogenic and able to bind their specif...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820783/ https://www.ncbi.nlm.nih.gov/pubmed/29466990 http://dx.doi.org/10.1186/s12951-018-0341-6 |
_version_ | 1783301427295158272 |
---|---|
author | Alric, Christophe Hervé-Aubert, Katel Aubrey, Nicolas Melouk, Souad Lajoie, Laurie Même, William Même, Sandra Courbebaisse, Yann Ignatova, Anastasia A. Feofanov, Alexey V. Chourpa, Igor Allard-Vannier, Emilie |
author_facet | Alric, Christophe Hervé-Aubert, Katel Aubrey, Nicolas Melouk, Souad Lajoie, Laurie Même, William Même, Sandra Courbebaisse, Yann Ignatova, Anastasia A. Feofanov, Alexey V. Chourpa, Igor Allard-Vannier, Emilie |
author_sort | Alric, Christophe |
collection | PubMed |
description | BACKGROUND: Recent advances in nanomedicine have shown the great interest of active targeting associated to nanoparticles. Single chain variable fragments (scFv) of disease-specific antibodies are very promising targeting entities because they are small, not immunogenic and able to bind their specific antigens. The present paper is devoted to biological properties in vitro and in vivo of fluorescent and pegylated iron oxide nanoparticles (SPIONs-Cy-PEG-scFv) functionalized with scFv targeting Human Epithelial growth Receptor 2 (HER2). RESULTS: Thanks to a site-selective scFv conjugation, the resultant nanoprobes demonstrated high affinity and specific binding to HER2 breast cancer cells. The cellular uptake of SPIONs-Cy-PEG-scFv was threefold higher than that for untargeted PEGylated iron oxide nanoparticles (SPIONs-Cy-PEG) and is correlated to the expression of HER2 on cells. In vivo, the decrease of MR signals in HER2+ xenograft tumor is about 30% at 24 h after the injection. CONCLUSIONS: These results all indicate that SPIONs-Cy-PEG-scFv are relevant tumor-targeting magnetic resonance imaging agents, suitable for diagnosis of HER2 overexpressing breast tumor. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12951-018-0341-6) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5820783 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-58207832018-02-26 Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes Alric, Christophe Hervé-Aubert, Katel Aubrey, Nicolas Melouk, Souad Lajoie, Laurie Même, William Même, Sandra Courbebaisse, Yann Ignatova, Anastasia A. Feofanov, Alexey V. Chourpa, Igor Allard-Vannier, Emilie J Nanobiotechnology Research BACKGROUND: Recent advances in nanomedicine have shown the great interest of active targeting associated to nanoparticles. Single chain variable fragments (scFv) of disease-specific antibodies are very promising targeting entities because they are small, not immunogenic and able to bind their specific antigens. The present paper is devoted to biological properties in vitro and in vivo of fluorescent and pegylated iron oxide nanoparticles (SPIONs-Cy-PEG-scFv) functionalized with scFv targeting Human Epithelial growth Receptor 2 (HER2). RESULTS: Thanks to a site-selective scFv conjugation, the resultant nanoprobes demonstrated high affinity and specific binding to HER2 breast cancer cells. The cellular uptake of SPIONs-Cy-PEG-scFv was threefold higher than that for untargeted PEGylated iron oxide nanoparticles (SPIONs-Cy-PEG) and is correlated to the expression of HER2 on cells. In vivo, the decrease of MR signals in HER2+ xenograft tumor is about 30% at 24 h after the injection. CONCLUSIONS: These results all indicate that SPIONs-Cy-PEG-scFv are relevant tumor-targeting magnetic resonance imaging agents, suitable for diagnosis of HER2 overexpressing breast tumor. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12951-018-0341-6) contains supplementary material, which is available to authorized users. BioMed Central 2018-02-21 /pmc/articles/PMC5820783/ /pubmed/29466990 http://dx.doi.org/10.1186/s12951-018-0341-6 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Alric, Christophe Hervé-Aubert, Katel Aubrey, Nicolas Melouk, Souad Lajoie, Laurie Même, William Même, Sandra Courbebaisse, Yann Ignatova, Anastasia A. Feofanov, Alexey V. Chourpa, Igor Allard-Vannier, Emilie Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes |
title | Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes |
title_full | Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes |
title_fullStr | Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes |
title_full_unstemmed | Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes |
title_short | Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes |
title_sort | targeting her2-breast tumors with scfv-decorated bimodal nanoprobes |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820783/ https://www.ncbi.nlm.nih.gov/pubmed/29466990 http://dx.doi.org/10.1186/s12951-018-0341-6 |
work_keys_str_mv | AT alricchristophe targetingher2breasttumorswithscfvdecoratedbimodalnanoprobes AT herveaubertkatel targetingher2breasttumorswithscfvdecoratedbimodalnanoprobes AT aubreynicolas targetingher2breasttumorswithscfvdecoratedbimodalnanoprobes AT melouksouad targetingher2breasttumorswithscfvdecoratedbimodalnanoprobes AT lajoielaurie targetingher2breasttumorswithscfvdecoratedbimodalnanoprobes AT memewilliam targetingher2breasttumorswithscfvdecoratedbimodalnanoprobes AT memesandra targetingher2breasttumorswithscfvdecoratedbimodalnanoprobes AT courbebaisseyann targetingher2breasttumorswithscfvdecoratedbimodalnanoprobes AT ignatovaanastasiaa targetingher2breasttumorswithscfvdecoratedbimodalnanoprobes AT feofanovalexeyv targetingher2breasttumorswithscfvdecoratedbimodalnanoprobes AT chourpaigor targetingher2breasttumorswithscfvdecoratedbimodalnanoprobes AT allardvannieremilie targetingher2breasttumorswithscfvdecoratedbimodalnanoprobes |